Advice for n-of-1 Drug Developers

The FDA has issued draft recommendations to help developers of antisense oligonucleotide (ASO) therapies for rare, debilitating genetic diseases to conduct human trials with a single participant, known as n-of-1 trials.
Source: JAMA - Category: General Medicine Source Type: research